DELETERIOUS EFFECTS OF INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM IN NEONATAL RATS

被引：10

作者：

CHARBIT, M ^{[1
]}

DECHAUX, M ^{[1
]}

BLAZY, I ^{[1
]}

VARGAS, R ^{[1
]}

LAOUARI, D ^{[1
]}

BROCART, D ^{[1
]}

LACOSTE, M ^{[1
]}

GUBLER, MC ^{[1
]}

SACHS, C ^{[1
]}

机构：

[1] CHU NECKER ENFANTS MALAD,DEPT PHYSIOL,F-75015 PARIS,FRANCE

来源：

PEDIATRIC NEPHROLOGY | 1995年 / 9卷 / 03期

关键词：

RENIN-ANGIOTENSIN SYSTEM; NEONATE; RAT; ANGIOTENSIN I CONVERTING ENZYME INHIBITOR; BLOOD PRESSURE; RENAL FUNCTION;

D O I：

10.1007/BF02254192

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The angiotensin I converting enzyme inhibitor (ACEI) perindopril (2 mg/kg body weight), the peripheral vasodilator dihydralazine (DHL) (25 mg/kg body weight) or distilled water was given daily from birth to day 14 to neonatal rats. Blood pressure, plasma creatinine, plasma renin activity (PRA), substrate (PRS) and concentration (PRC) and renin content of kidney tissue sections were evaluated on days 14 and 28. By day 14, a high mortality in the ACEI group was observed. ACEI, but not DHL, led to a significant fall (P < 0.01) in blood pressure, 57 +/- 11 versus 89 +/- 25 in the DHL group and 103 +/- 24 mmHg in controls, and to a dramatic increase in plasma creatinine. PRA and PRS were undetectable in ACEI-treated rats; in contrast, PRC and renal staining with anti-renin antibody were significantly increased in ACEI rats. On day 28, the blood pressure was normal in all groups and plasma creatinine returned to the normal range in ACEI rats. PRA, PRS and PRC were not significantly different in the ACEI group and controls. These results suggest that the renin-angiotensin system (RAS) plays a major postnatal role in the neonatal rat. Inhibition of the RAS during the first 2 weeks of life leads to high mortality, severe hypotension, reversible renal failure and a defect in circulating angiotensinogen.

引用

页码：303 / 308

页数：6

共 40 条

[1]

Guignard J.P., Burgener F., Calame A., Persistent anuria in a neonate. A side effect of captopril, Int J Nephrol, 53, pp. 243-252, (1981)

[2]

Rosa F.W., Bosco L.A., Fossum Graham C., Milstien J.B., Dreis M., Creamer J., Neonatal anuria with maternal angiotensinconverting enzyme inhibition, Obstet Gynecol, 74, pp. 371-374, (1989)

[3]

Cunniff C., Lyons Jones K., Phillipson J., Benirschke K., Short S., Wujek J., Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use, Am J Obstet Gynecol, 162, pp. 187-189, (1990)

[4]

Hanssens M., Keirse M.J.N.C., Vankelecom F., Van Assche F.A., Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy, Obstet Gynecol, 78, pp. 128-135, (1991)

[5]

Pryde P.G., Sedman A.B., Nugent C.E., Barr M., Angiotensin converting enzyme inhibitor fetopathy, J Am Soc Nephrol, 3, pp. 1575-1582, (1993)

[6]

Barr M., Cohen M., ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection, Teratology, 44, pp. 485-495, (1991)

[7]

Martin R.A., Jones K.L., Mendoza A., Barr M., Benirschke K., Effect of ACE inhibition on the fetal kidney: decreased renal blood flow, Teratology, 46, pp. 317-321, (1992)

[8]

Hoppe B., Neuhaus T., Weisser B., Leumann E., Clinical quiz, Pediatr Nephrol, 7, pp. 769-770, (1993)

[9]

Lieberman J., Elevation of serum angiotensin converting enzyme level in sarcoïdosis, Am J Med, 59, pp. 365-372, (1975)

[10]

Kagedal B., Olsson B., Determination of creatinine in serum by high-performance liquid chromatography: a comparison of three ion-exchange methods, J Chromatogr, 527, pp. 21-30, (1990)

← 1 2 3 4 →